Adcirca and Primary pulmonary hypertension - a phase IV clinical study of FDA data
Summary:
Primary pulmonary hypertension is found among people who take Adcirca, especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months.
The phase IV clinical study analyzes which people take Adcirca and have Primary pulmonary hypertension. It is created by eHealthMe based on reports of 49,298 people who have side effects when taking Adcirca from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.
With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Most recently, phase IV clinial trails for COVID 19 vaccines have been added, check here.
49,298 people reported to have side effects when taking Adcirca.
Among them, 2,329 people (4.72%) have Primary pulmonary hypertension.
What is Adcirca?
Adcirca has active ingredients of tadalafil. It is often used in pulmonary hypertension. eHealthMe is studying from 49,346 Adcirca users for its effectiveness, alternative drugs and more.
What is Primary pulmonary hypertension?
Primary pulmonary hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart) is found to be associated with 1,066 drugs and 655 conditions by eHealthMe.
Number of Adcirca and Primary pulmonary hypertension reports submitted per year:
Time on Adcirca when people have Primary pulmonary hypertension *:
Gender of people who have Primary pulmonary hypertension when taking Adcirca*:
Age of people who have Primary pulmonary hypertension when taking Adcirca *:
Common drugs people take besides Adcirca *:
Common side effects people have besides Primary pulmonary hypertension *:
Common conditions people have *:
* Approximation only. Some reports may have incomplete information.
Do you take Adcirca and have Primary pulmonary hypertension?
Check whether Primary pulmonary hypertension is associated with a drug or a conditionHow to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Related studies
Alternative drugs to, pros and cons of Adcirca:
- Adcirca (49,346 reports)
Primary pulmonary hypertension treatments and more:
- Primary pulmonary hypertension (183,320 reports)
COVID vaccines that are related to Primary pulmonary hypertension:
- Primary pulmonary hypertension in Moderna COVID Vaccine
- Primary pulmonary hypertension in Pfizer BioNTech Covid Vaccine
- Primary pulmonary hypertension in Johnson and Johnson Covid Vaccine
How severe was Primary pulmonary hypertension and when was it recovered:
Expand to all the drugs that have ingredients of tadalafil:
Common drugs associated with Primary pulmonary hypertension:
- Adcirca: 2,329 reports
- Adempas: 956 reports
- Albuterol: 235 reports
- Aldactone: 366 reports
- Allopurinol: 269 reports
- Alprazolam: 104 reports
- Ambrisentan: 1,692 reports
- Amlodipine: 458 reports
- Aspirin: 567 reports
- Bumetanide: 116 reports
- Bumex: 135 reports
- Coumadin: 1,145 reports
- Cyclophosphamide: 146 reports
- Digoxin: 426 reports
- Eliquis: 422 reports
- Epoprostenol sodium: 168 reports
- Flolan: 336 reports
- Flonase: 115 reports
- Furosemide: 974 reports
- Gabapentin: 232 reports
- Ibuprofen: 106 reports
- Lasix: 900 reports
- Letairis: 1,735 reports
- Lipitor: 163 reports
- Lisinopril: 186 reports
- Lopurin: 269 reports
- Loraz: 114 reports
- Lorazepam: 114 reports
- Metformin: 225 reports
- Methotrexate: 151 reports
- Metolazone: 222 reports
- Morphine: 116 reports
- Nexium: 205 reports
- Nifedipine: 125 reports
- Omeprazole: 343 reports
- Ondansetron: 146 reports
- Opsumit: 3,069 reports
- Orenitram: 576 reports
- Pantoprazole: 316 reports
- Plavix: 168 reports
- Potassium: 225 reports
- Prednisolone: 130 reports
- Prednisone: 489 reports
- Prilosec: 132 reports
- Profen: 106 reports
- Protonix: 140 reports
- Remodulin: 2,322 reports
- Revatio: 1,742 reports
- Sertraline: 108 reports
- Sildenafil citrate: 518 reports
- Simvastatin: 170 reports
- Spiriva: 190 reports
- Spironolactone: 768 reports
- Symbicort: 120 reports
- Synthroid: 178 reports
- Tadalafil: 488 reports
- Torsemide: 242 reports
- Tracleer: 2,521 reports
- Tramadol: 189 reports
- Treprostinil: 200 reports
- Tylenol: 136 reports
- Tyvaso: 1,293 reports
- Uptravi: 1,450 reports
- Veletri: 1,289 reports
- Ventavis: 613 reports
- Vitamin d: 179 reports
- Xanax: 134 reports
- Xarelto: 391 reports
- Zofran: 121 reports
All the drugs that are associated with Primary pulmonary hypertension:
- Primary pulmonary hypertension (1,066 drugs)
Common conditions associated with Primary pulmonary hypertension:
- Antidepressant therapy: 151 reports
- Atrial fibrillation/flutter: 109 reports
- Cardiac failure: 152 reports
- Chronic myeloid leukaemia: 120 reports
- Cor pulmonale chronic: 194 reports
- Depression: 155 reports
- Diabetes: 134 reports
- Familial primary pulmonary hypertension: 4,249 reports
- Gastroesophageal reflux disease: 110 reports
- High blood pressure: 254 reports
- Hypertension: 234 reports
- Multiple sclerosis: 115 reports
- Pain: 134 reports
- Primary pulmonary hypertension: 3,626 reports
- Pulmonary arterial hypertension: 4,249 reports
- Pulmonary hypertension: 2,110 reports
- Sporadic primary pulmonary hypertension: 4,249 reports
- Systemic sclerosis (scleroderma): 148 reports
All the conditions that are associated with Primary pulmonary hypertension:
- Primary pulmonary hypertension (655 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on tadalafil (the active ingredients of Adcirca) and Adcirca (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Arava and Joint Swelling - now
- Acetaminophen and Heart Disease - 4 seconds ago
- Cefepime Hydrochloride and Linezolid drug interaction - 11 seconds ago
- Cialis and Botox drug interaction - 16 seconds ago
- Perjeta and Thrombocytopenia - 19 seconds ago